<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33583639</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1166</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Human immunology</Title><ISOAbbreviation>Hum Immunol</ISOAbbreviation></Journal><ArticleTitle>The role of immune-mediated alterations and disorders in ALS disease.</ArticleTitle><Pagination><StartPage>155</StartPage><EndPage>161</EndPage><MedlinePgn>155-161</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.humimm.2021.01.017</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0198-8859(21)00038-0</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that leads to neuronal death in the brain and spinal cord. Over the last decades, evidence has emerged regarding the functional diversity of astrocytes, microglia, and T cells in the central nervous system (CNS), and the role of neuroinflammation in ALS. In this review, we summarize current knowledge regarding neuroinflammation in ALS, both at the level of specific molecular pathways and potential cellular pathways as well as outline questions about the immune mechanisms involved in ALS pathogenesis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rodrigues Lima-Junior</LastName><ForeName>Jo&#xe3;o</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>La Jolla Institute for Immunology, Center for Autoimmunity and Inflammation, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sulzer</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University; New York State Psychiatric Institute, New York, NY 10032, USA; Departments of Psychiatry and Pharmacology, Columbia University; New York State Psychiatric Institute, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindestam Arlehamn</LastName><ForeName>Cecilia S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>La Jolla Institute for Immunology, Center for Autoimmunity and Inflammation, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sette</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>La Jolla Institute for Immunology, Center for Autoimmunity and Inflammation, La Jolla, CA 92037, USA; Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA. Electronic address: alex@lji.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS095435</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Immunol</MedlineTA><NlmUniqueID>8010936</NlmUniqueID><ISSNLinking>0198-8859</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015551" MajorTopicYN="N">Autoimmunity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020078" MajorTopicYN="N">Neurogenic Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Autoimmunity</Keyword><Keyword MajorTopicYN="N">Glial cells</Keyword><Keyword MajorTopicYN="N">Neuroinflammation</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>15</Day><Hour>5</Hour><Minute>39</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33583639</ArticleId><ArticleId IdType="mid">NIHMS1673848</ArticleId><ArticleId IdType="pmc">PMC7942756</ArticleId><ArticleId IdType="doi">10.1016/j.humimm.2021.01.017</ArticleId><ArticleId IdType="pii">S0198-8859(21)00038-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mehta P, Kaye W, Raymond J, Punjani R, Larson T, Cohen J. Prevalence of Amyotrophic Lateral Sclerosis. Morb Mortal Wkly Rep. 2018;67(46):1285&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6289079</ArticleId><ArticleId IdType="pubmed">30462626</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabatelli M, Conte A, Zollino M. Clinical and genetic heterogeneity of amyotrophic lateral sclerosis. Clin Genet. 2013;83(5):408&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">23379621</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362(6415):59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science (80-). 2008;319(5870):1668&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. Neuron [Internet]. 2011;72(2):245&#x2013;56. Available from: 10.1016/j.neuron.2011.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen HP, Van Broeckhoven C, van der Zee J. ALS Genes in the Genomic Era and their Implications for FTD. Trends Genet [Internet]. 2018;34(6):404&#x2013;23. Available from: 10.1016/j.tig.2018.03.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tig.2018.03.001</ArticleId><ArticleId IdType="pubmed">29605155</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Wang F. Role of neuroinflammation in amyotrophic lateral sclerosis: Cellular mechanisms and therapeutic implications. Front Immunol. 2017;8(AUG):1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567007</ArticleId><ArticleId IdType="pubmed">28871262</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Zhao W, Liao B, Kano O, Wang J, Huang A, et al. Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice. Brain Behav Immun [Internet]. 2011;25(5):1025&#x2013;35. Available from: 10.1016/j.bbi.2010.12.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2010.12.008</ArticleId><ArticleId IdType="pmc">PMC3096756</ArticleId><ArticleId IdType="pubmed">21176785</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooten KG, Beers DR, Zhao W, Appel SH. Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis. Neurotherapeutics. 2015;12(2):364&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4404435</ArticleId><ArticleId IdType="pubmed">25567201</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Q, Zhou Q, Chen Y, Ou R, Cao B, Xu Y, et al. Analysis of SOD1 mutations in a Chinese population with amyotrophic lateral sclerosis: A case-control study and literature review. Sci Rep. 2017;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5349524</ArticleId><ArticleId IdType="pubmed">28291249</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunton-Stasyshyn RKA, Saccon RA, Fratta P, Fisher EMC. SOD1 Function and Its Implications for Amyotrophic Lateral Sclerosis Pathology: New and Renascent Themes. Neuroscientist. 2015;21(5):519&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">25492944</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Front Neurosci. 2019;13(December):1&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita S, Ando Y. Genotype-phenotype relationship in hereditary amyotrophic lateral sclerosis. Translational Neurodegeneration. 2015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4513711</ArticleId><ArticleId IdType="pubmed">26213621</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier M, Welt T, Wirth F, Montrasio F, Preisig D, McAfoose J, et al. A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms in mouse models of amyotrophic lateral sclerosis. Sci Transl Med. 2018;</Citation><ArticleIdList><ArticleId IdType="pubmed">30518612</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondola P, Damiano S, Sasso A, Santillo M. The Cu, Zn superoxide dismutase: Not only a dismutase enzyme. Front Physiol. 2016;7(NOV):1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5126113</ArticleId><ArticleId IdType="pubmed">27965593</ArticleId></ArticleIdList></Reference><Reference><Citation>Johann S, Heitzer M, Kanagaratnam M, Goswami A, Rizo T, Weis J, et al. NLRP3 inflammasome is expressed by astrocytes in the SOD1 mouse model of ALS and in human sporadic ALS patients. Glia. 2015;63(12):2260&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">26200799</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science (80-). 1994;264(5166): 1772&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Wang H, Kouadir M, Song H, Shi F. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis [Internet], 2019; 10(2). Available from: 10.1038/s41419-019-1413-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-019-1413-8</ArticleId><ArticleId IdType="pmc">PMC6372664</ArticleId><ArticleId IdType="pubmed">30755589</ArticleId></ArticleIdList></Reference><Reference><Citation>Aebischer J, Cassina P, Otsmane B, Moumen A, Seilhean D, Meininger V, et al. IFN&#x3b3; triggers a LIGHT-dependent selective death of motoneurons contributing to the non-cell-autonomous effects of mutant SOD1. Cell Death Differ [Internet], 2011; 18(5):754&#x2013;68. Available from: 10.1038/cdd.2010.143</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2010.143</ArticleId><ArticleId IdType="pmc">PMC3131923</ArticleId><ArticleId IdType="pubmed">21072055</ArticleId></ArticleIdList></Reference><Reference><Citation>Majchrzak M, Drela K, Andrzejewska A, Rogujski P, Figurska S, Fiedorowicz M, et al. SOD1/Rag2 Mice with Low Copy Number of SOD1 Gene as a New Long-Living Immunodeficient Model of ALS. Sci Rep [Internet], 2019;9(1): 1&#x2013;13. Available from: 10.1038/s41598-018-37235-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-37235-w</ArticleId><ArticleId IdType="pmc">PMC6349855</ArticleId><ArticleId IdType="pubmed">30692571</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann DH, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci. 2008;11(3):251&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3137510</ArticleId><ArticleId IdType="pubmed">18246065</ArticleId></ArticleIdList></Reference><Reference><Citation>Endo F, Komine O, Fujimori-Tonou N, Katsuno M, Jin S, Watanabe S, et al. Astrocyte-Derived TGF-&#x3b2;1 Accelerates Disease Progression in ALS Mice by Interfering with the Neuroprotective Functions of Microglia and T Cells. Cell Rep [Internet], 2015;11(4):592&#x2013;604. Available from: 10.1016/j.celrep.2015.03.053</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.03.053</ArticleId><ArticleId IdType="pubmed">25892237</ArticleId></ArticleIdList></Reference><Reference><Citation>Itzecka J, Stelmasiak Z, Dobosz B. Transforming growth factor-beta 1 (TGF-beta 1) in patients with amyotrophic lateral sclerosis. Cytokine. 2002;20(5):239&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">12550109</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandelman M, Peluffo H, Beckman JS, Cassina P, Barbeito L. Extracellular ATP and the P2X7receptor in astrocyte-mediated motor neuron death: Implications for amyotrophic lateral sclerosis. J Neuroinflammation. 2010;7:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2901222</ArticleId><ArticleId IdType="pubmed">20534165</ArticleId></ArticleIdList></Reference><Reference><Citation>Rietdijk CD, Wezel RJA Van, Garssen J, Kraneveld AD. Neuronal toll-like receptors and neuro-immunity in Parkinson&#x2019;s disease, Alzheimer&#x2019;s disease and stroke. 2016;27&#x2013;37.</Citation></Reference><Reference><Citation>Zindel J, Kubes P. DAMPs, PAMPs, and LAMPs in Immunity and Sterile Inflammation. Annu Rev Pathol Mech Dis. 2020;15(1):493&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pubmed">31675482</ArticleId></ArticleIdList></Reference><Reference><Citation>Letiembre M, Liu Y, Walter S, Hao W, Pfander T, Wrede A, et al. Screening of innate immune receptors in neurodegenerative diseases: A similar pattern. Neurobiol Aging. 2009;30(5):759&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">17905482</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Hao W, Dawson A, Liu S, Fassbender K. Expression of amyotrophic lateral sclerosis-linked SOD1 mutant increases the neurotoxic potential of microglia via TLR2. J Biol Chem. 2009;284(6):3691&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19091752</ArticleId></ArticleIdList></Reference><Reference><Citation>Forrester SJ, Kikuchi DS, Hernandes MS, Xu Q, Griendling KK. Reactive oxygen species in metabolic and inflammatory signaling. Circulation Research. 2018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5926825</ArticleId><ArticleId IdType="pubmed">29700084</ArticleId></ArticleIdList></Reference><Reference><Citation>De Paola M, Sestito SE, Mariani A, Memo C, Fanelli R, Freschi M, et al. Synthetic and natural small molecule TLR4 antagonists inhibit motoneuron death in cultures from ALS mouse model. Pharmacol Res [Internet], 2016;103:180&#x2013;7. Available from: 10.1016/j.phrs.2015.11.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2015.11.020</ArticleId><ArticleId IdType="pubmed">26640075</ArticleId></ArticleIdList></Reference><Reference><Citation>Meissner F, Molawi K, Zychlinsky A. Mutant superoxide dismutase 1-induced IL-1&#x3b2; accelerates ALS pathogenesis. Proc Natl Acad Sci U S A. 2010; 107(29): 13046&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919927</ArticleId><ArticleId IdType="pubmed">20616033</ArticleId></ArticleIdList></Reference><Reference><Citation>Casula M, Iyer AM, Spliet WGM, Anink JJ, Steentjes K, Sta M, et al. Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue. Neuroscience [Internet], 2011;179:233&#x2013;43. Available from: 10.1016/j.neuroscience.2011.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2011.02.001</ArticleId><ArticleId IdType="pubmed">21303685</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A, Bharathi V, Sivalingam V, Girdhar A, Patel BK. Molecular mechanisms of TDP-43 misfolding and pathology in amyotrophic lateral sclerosis. Front Mol Neurosci. 2019; 12(February): 1&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6382748</ArticleId><ArticleId IdType="pubmed">30837838</ArticleId></ArticleIdList></Reference><Reference><Citation>Yl Noto, Shibuya K, Sato Y, Kanai K, Misawa S, Sawai S, et al. Elevated CSF TDP-43 levels in amyotrophic lateral sclerosis: Specificity, sensitivity, and a possible prognostic value. Amyotroph Lateral Scler. 2011. ;12(2): 140&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">21126161</ArticleId></ArticleIdList></Reference><Reference><Citation>Iguchi Y, Eid L, Parent M, Soucy G, Bareil C, Riku Y, et al. Exosome secretion is a key pathway for clearance of pathological TDP-43. Brain. 2016;139(12):3187&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5840881</ArticleId><ArticleId IdType="pubmed">27679482</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Bell S, Wang J, Wen S, Baloh RH, et al. TDP-43 activates microglia through NF-&#x3ba;B and NLRP3 inflammasome. Exp Neurol [Internet], 2015;273:24&#x2013;35. Available from: 10.1016/j.expneurol.2015.07.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2015.07.019</ArticleId><ArticleId IdType="pubmed">26222336</ArticleId></ArticleIdList></Reference><Reference><Citation>Correia AS, Patel P, Dutta K, Julien JP. Inflammation induces TDP-43 mislocalization and aggregation. PLoS One. 2015; 10(10): 1&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4596857</ArticleId><ArticleId IdType="pubmed">26444430</ArticleId></ArticleIdList></Reference><Reference><Citation>Leal-Lasarte MM, Franco JM, Labrador-Garrido A, Pozo D, Roodveldt C. Extracellular TDP-43 aggregates target MAPK/MAK/MRK overlapping kinase (MOK) and trigger caspase-3/IL-18 signaling in microglia. FASEB J. 2017;31(7):2797&#x2013;816.</Citation><ArticleIdList><ArticleId IdType="pubmed">28336525</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombo E, Farina C. Astrocytes: Key Regulators of Neuroinflammation. Trends Immunol. 2016;37(9):608&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">27443914</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephenson DT, Stephenson DT, Wright S. Reactive astrogliosis is widespread in the subcortical white matter of amyotrophic lateral sclerosis brain. Vol. 50, Journal of Neuropathology and Experimental Neurology. 1991. p. 263&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">2022968</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffer D, Cordera S, Cavalla P, Migheli A. Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J Neurol Sci. 1996;139(SUPPL.):27&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">8899654</ArticleId></ArticleIdList></Reference><Reference><Citation>Song SW, Miranda CJ, Braun L, Meyer K, Frakes AE, Ferraiuolo L, et al. Major histocompatibility complex class I molecules protect motor neurons from astrocyte-induced toxicity in amyotrophic lateral sclerosis. Nat Med. 2016;22(4):397&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4823173</ArticleId><ArticleId IdType="pubmed">26928464</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes C, Cunha C, Nascimento F, Ribeiro JA, Vaz AR, Brites D. Cortical Neurotoxic Astrocytes with Early ALS Pathology and miR-146a Deficit Replicate Gliosis Markers of Symptomatic SOD1G93A Mouse Model. Mol Neurobiol. 2019;56(3):2137&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">29995256</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyzack GE, Hall CE, Sibley CR, Cymes T, Forostyak S, Carlino G, et al. A neuroprotective astrocyte state is induced by neuronal signal EphB1 but fails in ALS models. Nat Commun [Internet]. 2017;8(1). Available from: 10.1038/s41467-017-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-01283-z</ArticleId><ArticleId IdType="pmc">PMC5660125</ArticleId><ArticleId IdType="pubmed">29079839</ArticleId></ArticleIdList></Reference><Reference><Citation>Voet S, Srinivasan S, Lamkanfi M, Loo G. Inflammasomes in neuroinflammatory and neurodegenerative diseases. EMBO Mol Med. 2019;11(6):1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6554670</ArticleId><ArticleId IdType="pubmed">31015277</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman L, Guo H, David CN, Brickey WJ, Jha S, Ting JPY. NLR members NLRC4 and NLRP3 mediate sterile inflammasome activation in microglia and astrocytes. J Exp Med. 2017;214(5):1351&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5413320</ArticleId><ArticleId IdType="pubmed">28404595</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf SA, Boddeke HWGM, Kettenmann H. Microglia in Physiology and Disease. Annu Rev Physiol. 2017;79(1):619&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">27959620</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Cagnin A, Turkheimer FE, Miller CCJ, Shaw CE, Brooks DJ, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: An [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis. 2004;15(3):601&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15056468</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaz AR, Pinto S, Ezequiel C, Cunha C, Carvalho LA, Moreira R, et al. Phenotypic effects of wild-type and mutant SOD1 expression in n9 murine microglia at steady state, inflammatory and immunomodulatory conditions. Front Cell Neurosci. 2019;13(April):1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6465643</ArticleId><ArticleId IdType="pubmed">31024256</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray R, Juranek JK, Rai V. RAGE axis in neuroinflammation, neurodegeneration and its emerging role in the pathogenesis of amyotrophic lateral sclerosis. Neurosci Biobehav Rev [Internet]. 2016;62:48&#x2013;55. Available from: 10.1016/j.neubiorev.2015.12.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2015.12.006</ArticleId><ArticleId IdType="pubmed">26724598</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JD, Liu N, Levin SC, Ottosson L, Andersson U, Harris HE, et al. Therapeutic blockade of HMGB1 reduces early motor deficits, but not survival in the SOD1G93A mouse model of amyotrophic lateral sclerosis. J Neuroinflammation. 2019;16(1):1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380064</ArticleId><ArticleId IdType="pubmed">30782181</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JD, McDonald TS, Fung JNT, Woodruff TM. Absence of Receptor for Advanced Glycation End Product (RAGE) Reduces Inflammation and Extends Survival in the hSOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis. Mol Neurobiol. 2020;57(10):4143&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">32676989</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttenplan KA, Weigel MK, Adler DI, Couthouis J, Liddelow SA, Gitler AD, et al. Knockout of reactive astrocyte activating factors slows disease progression in an ALS mouse model. Nat Commun [Internet]. 2020;11(1):1&#x2013;9. Available from: 10.1038/s41467-020-17514-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17514-9</ArticleId><ArticleId IdType="pmc">PMC7385161</ArticleId><ArticleId IdType="pubmed">32719333</ArticleId></ArticleIdList></Reference><Reference><Citation>Boill&#xe9;e S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science (80-). 2006;312(5778):1389&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Henkel JS, Xiao Q, Zhao W, Wang J, Yen AA, et al. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2006;103(43):16021&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1613228</ArticleId><ArticleId IdType="pubmed">17043238</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao B, Zhao W, Beers DR, Henkel JS, Appel SH. Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp Neurol [Internet]. 2012;237(1):147&#x2013;52. Available from: 10.1016/j.expneurol.2012.06.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2012.06.011</ArticleId><ArticleId IdType="pmc">PMC4126417</ArticleId><ArticleId IdType="pubmed">22735487</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravel M, Beland LC, Soucy G, Abdelhamid E, Rahimian R, Gravel C, et al. II-10 controls early microglial phenotypes and disease onset in ALS caused by misfolded superoxide dismutase 1. J Neurosci. 2016;36(3):1031&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6601999</ArticleId><ArticleId IdType="pubmed">26791230</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Thonhoff JR, Thome AD, Faridar A, Wang J, et al. Immunosuppressive Functions of M2 Macrophages Derived from iPSCs of Patients with ALS and Healthy Controls. Vol. 23, iScience. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7286967</ArticleId><ArticleId IdType="pubmed">32521508</ArticleId></ArticleIdList></Reference><Reference><Citation>Lall D, Baloh RH. Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia. J Clin Invest. 2017;127(9):3250&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5669558</ArticleId><ArticleId IdType="pubmed">28737506</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Q, Jiao B, Shen L. The Development of C9orf72-Related Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Disorders. Frontiers in Genetics. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7492664</ArticleId><ArticleId IdType="pubmed">32983232</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M, Belzil VV, Batra R, Ross CA, Gendron TF, Pregent LJ, et al. Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS. Nat Neurosci. 2015;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4830686</ArticleId><ArticleId IdType="pubmed">26192745</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke JG, Bogdanik L, Y&#xe1;&#xf1;ez A, Lall D, Wolf AJ, Muhammad AKMG, et al. C9orf72 is required for proper macrophage and microglial function in mice. Science (80-). 2016;351(6279):1324&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120541</ArticleId><ArticleId IdType="pubmed">26989253</ArticleId></ArticleIdList></Reference><Reference><Citation>Olesen MN, Wuolikainen A, Nilsson AC, Wirenfeldt M, Forsberg K, Madsen JS, et al. Inflammatory profiles relate to survival in subtypes of amyotrophic lateral sclerosis. Neurol Neuroimmunol neuroinflammation. 2020;7(3).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7136052</ArticleId><ArticleId IdType="pubmed">32123048</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan PM, Zhou X, Robins AM, Paushter DH, Kim D, Smolka MB, et al. The ALS/FTLD associated protein C9orf72 associates with SMCR8 and WDR41 to regulate the autophagy-lysosome pathway. Acta Neuropathol Commun [Internet]. 2016;4(1):51. Available from: 10.1186/s40478-016-0324-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0324-5</ArticleId><ArticleId IdType="pmc">PMC4870812</ArticleId><ArticleId IdType="pubmed">27193190</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Toledo JB, van Deerlin VM, Elman L, McCluskey L, Lee VMY, et al. Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLoS One. 2012;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375234</ArticleId><ArticleId IdType="pubmed">22720079</ArticleId></ArticleIdList></Reference><Reference><Citation>Atanasio A, Decman V, White D, Ramos M, Ikiz B, Lee HC, et al. C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice. Sci Rep. 2016;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4793236</ArticleId><ArticleId IdType="pubmed">26979938</ArticleId></ArticleIdList></Reference><Reference><Citation>Burberry A, Suzuki N, Wang JY, Moccia R, Mordes DA, Stewart MH, et al. Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Sci Transl Med. 2016;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024536</ArticleId><ArticleId IdType="pubmed">27412785</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel SH, Stockton Appel V, Stewart SS, Kerman RH. Amyotrophic Lateral Sclerosis: Associated Clinical Disorders and Immunological Evaluations. Arch Neurol. 1986;43(3):234&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">3484947</ArticleId></ArticleIdList></Reference><Reference><Citation>TROOST D, van den OORD JJ, JONG JMBV DE. Immunohistochemical characterization of the inflammatory infiltrate in amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol. 1990;16(5):401&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">2263315</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt JI, Tajti J, Appel SH. Lymphocytic Infiltrates in the Spinal Cord in Amyotrophic Lateral Sclerosis. Arch Neurol. 1993;50(1):30&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">8093428</ArticleId></ArticleIdList></Reference><Reference><Citation>Graves MC, Fiala M, Dinglasan LAV, Liu NQ, Sayre J, Chiappelli F, et al. Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and t cells. Amyotroph Lateral Scler Other Mot Neuron Disord. 2004;5(4):213&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15799549</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani S, Garbelli S, Pasini A, Alimonti D, Perotti C, Melazzini M, et al. Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process. J Neuroimmunol [Internet]. 2009;210(1&#x2013;2):73&#x2013;9. Available from: 10.1016/j.jneuroim.2009.02.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2009.02.012</ArticleId><ArticleId IdType="pubmed">19307024</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Henkel JS, Zhao W, Wang J, Appel SH. CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc Natl Acad Sci U S A. 2008;105(40):15558&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2547419</ArticleId><ArticleId IdType="pubmed">18809917</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu IM, Chen A, Zheng Y, Kosaras B, Tsiftsoglou SA, Vartanian TK, et al. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc Natl Acad Sci U S A. 2008;105(46):17913&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2581614</ArticleId><ArticleId IdType="pubmed">18997009</ArticleId></ArticleIdList></Reference><Reference><Citation>Sta M, Sylva-Steenland RMR, Casula M, Jong JMBV, Troost D, Aronica E, et al. Innate and adaptive immunity in amyotrophic lateral sclerosis: Evidence of complement activation. Neurobiol Dis. 2011;</Citation><ArticleIdList><ArticleId IdType="pubmed">21220013</ArticleId></ArticleIdList></Reference><Reference><Citation>Coque E, Salsac C, Espinosa-Carrasco G, Varga B, Degauque N, Cadoux M, et al. Cytotoxic CD8 + T lymphocytes expressing ALS-causing SOD1 mutant selectively trigger death of spinal motoneurons. Proc Natl Acad Sci U S A. 2019;116(6):2312&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6369778</ArticleId><ArticleId IdType="pubmed">30674678</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucca LE, Dominguez-Villar M. Modulation of regulatory T cell function and stability by co-inhibitory receptors. Nat Rev Immunol [Internet]. 2020; Available from: 10.1038/s41577-020-0296-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0296-3</ArticleId><ArticleId IdType="pubmed">32269380</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Henkel JS, Zhao W, Wang J, Huang A, Wen S, et al. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain. 2011;134(5):1293&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3097891</ArticleId><ArticleId IdType="pubmed">21596768</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Wen S, Rivera AL, Toennis KM, Appel JE, et al. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med. 2013;5(1):64&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3569654</ArticleId><ArticleId IdType="pubmed">23143995</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheean RK, McKay FC, Cretney E, Bye CR, Perera ND, Tomas D, et al. Association of regulatory T-Cell Expansion with progression of amyotrophic lateral sclerosis a study of humans and a transgenic mouse model. JAMA Neurol. 2018;75(6):681&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885208</ArticleId><ArticleId IdType="pubmed">29507931</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR. Tregs in ALS are Dysfunctional and Predict Progression Rate and Severity. JCI Insight. 2017;2(5):1&#x2013;14.</Citation></Reference><Reference><Citation>Alsuliman A, Appel SH, Beers DR, Basar R, Shaim H, Kaur I, et al. A robust, good manufacturing practice&#x2013;compliant, clinical-scale procedure to generate regulatory T cells from patients with amyotrophic lateral sclerosis for adoptive cell therapy. Cytotherapy [Internet]. 2016;18(10):1312&#x2013;24. Available from: 10.1016/j.jcyt.201606012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcyt.201606012</ArticleId><ArticleId IdType="pubmed">27497700</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff JR, Beers DR, Zhao W, Pleitez M, Simpson EP, Berry JD, et al. Expanded autologous regulatory T-lymphocyte infusions in ALS A phase I, first-in human study. Neurol Neuroimmunol NeuroInflammation. 2018;5(4).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5961523</ArticleId><ArticleId IdType="pubmed">29845093</ArticleId></ArticleIdList></Reference><Reference><Citation>Korn T, Kallies A. T cell responses in the central nervous system. Nat Rev Immunol. 2017;17(3):179&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">28138136</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes GM, Woodroofe MN, Cuzner ML. Microglia are the major cell type expressing MHC class II in human white matter. J Neurol Sci. 1987;80(1):25&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">3302117</ArticleId></ArticleIdList></Reference><Reference><Citation>Abellanas MA, Zamarbide M, Basurco L, Luquin E, Garcia-Granero M, Clavero P, et al. Midbrain microglia mediate a specific immunosuppressive response under inflammatory conditions. J Neuroinflammation. 2019;16(1):1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6874825</ArticleId><ArticleId IdType="pubmed">31757220</ArticleId></ArticleIdList></Reference><Reference><Citation>Arase N, Arase H. Cellular misfolded proteins rescued from degradation by MHC class II molecules are possible targets for autoimmune diseases. J Biochem. 2015; 158(5):367&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">26381536</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsonego A, Zota V, Karni A, Krieger J I, Bar-or A, Bitan G, et al. Increased T cell reactivity to amyloid &#x3b2; protein in older humans. J Clin Invest. 2003; 112(3):415&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC166296</ArticleId><ArticleId IdType="pubmed">12897209</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulzer D, Alcalay RN, Garretti F, Cote L, Kanter E, Agin-Liebes J, et al. T cells from patients with Parkinson&#x2019;s disease recognize &#x3b1;-synuclein peptides. Nature [Internet], 2017;546(7660):656&#x2013;61. Available from: 10.1038/nature22815</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22815</ArticleId><ArticleId IdType="pmc">PMC5626019</ArticleId><ArticleId IdType="pubmed">28636593</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindestam Arlehamn CS, Dhanwani R, Pham J, Kuan R, Frazier A, Rezende Dutra J, et al. &#x3b1;-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson&#x2019;s disease. Nat Commun. 2020; 11(1).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7171193</ArticleId><ArticleId IdType="pubmed">32313102</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindestam Arlehamn CS, Pham J, Alcalay RN, Frazier A, Shorr E, Carpenter C, et al. Widespread Tau-Specific CD4 T Cell Reactivity in the General Population. J Immunol. 2019;203(1):84&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6581570</ArticleId><ArticleId IdType="pubmed">31085590</ArticleId></ArticleIdList></Reference><Reference><Citation>Panzara MA, Gussoni E, Begovich AB, Murray RS, Zang YQ, Appel SH, et al. T cell receptor BV gene rearrangements in the spinal cords and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Neurobiol Dis. 1999;6(5):392&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">10527806</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>